Pharmafile Logo
Pharmafocus logo
Advanced Search

schizophrenia

Showing 15 posts of 29 posts found.

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023
Medical Communications FDA, Karuna Therapeutics, NDA, Neurology, schizophrenia

Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023
Medical Communications FDA, Karuna Therapeutics, Neurology, mental health, schizophrenia

Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …

News
brainss

Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

July 3, 2023
Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia

Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …

News

Newron announce successful results from schizophrenia study

April 1, 2021
schizophrenia

Newron, a biopharmaceutical company focused on novel therapies, have announced the initial results from two short-term exploratory studies assessing the …

News
europe-1395916_640

EMA receives filing for Janssen’s twice-yearly schizophrenia jab

December 7, 2020
Sales and Marketing EMA, Janssen, schizophrenia

The European Medicines Agency (EMA) has received Janssen’s Marketing Authorisation Extension for paliperidone palmitate six-monthly (PP6M), an injectable therapy administered …

News
aripiprazoleabilify

Clinical trial suggests new schizophrenia drug could reduce symptoms

April 16, 2020
Business Services D2, clinical trials, schizophrenia

Results from a newly published clinical trial suggest that a new compound could treat a broad range of schizophrenia symptoms. …

News

FDA approves first and only transdermal patch for schizophrenia

October 16, 2019
Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia

Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …

News
schizophrenia

Acadia’s schizophrenia drug flops in Phase 3 trial

July 23, 2019
Manufacturing and Production acadia, clinical trials, menatl health, neuroscience, pharma, phase 3, schizophrenia

Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …

News
5204602349_c87b204860_z

FDA delays Newron Pharmaceuticals’ trial into schizophrenia drug evenamide

May 28, 2019
Manufacturing and Production Newron Pharma, evenamide, pharma, schizophrenia

Newron Pharmaceuticals has halted a clinical trial of its schizophrenia drug evenamide after the FDA raised concerns about reports of …

News
neurons-3743011_960_720

Vitamin D deficiency may cause cognitive decline through weakening brain’s scaffolding

February 26, 2019
Manufacturing and Production NPP, mental health, neurology, neuroscience, schizophrenia, vitamin d

Vitamin D deficiency may weaken supportive ‘scaffolding’ in the brain thus causing neurons difficulty in maintaining connections, according to a …

News
schizophrenia_fmri_working_memory

Cambridgeshire and Peterborough NHS Foundation Trust launches mental health clinical trials

February 4, 2019
Sales and Marketing UK, clinical trials, clozapine, mental health, schizophrenia

The Cambridgeshire and Peterborough NHS Foundation Trust’s Windsor Research Unit is offering patients the chance to participate in clinical trials …

News
psm_v46_d168_mesial_view_of_the_human_brain

Commonly used heart and diabetes drugs may improve mental health, study finds

January 10, 2019
Research and Development UCL, bipolar, mental health, research, schizophrenia

Commonly used anti-cholesterol drugs, blood pressure drugs and medicines used for diabetes may improve the mental health of those with …

News
otsuka_web

Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3

August 1, 2018
Research and Development, Sales and Marketing Astex, Otsuka, Rxulti, guadecitabine, pharma, schizophrenia

It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) …

News
astrazeneca_sign_sky

AstraZeneca jettisons schizophrenia drug for $538 million

May 8, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Luye Pharma, Seroquel, pharma, schizophrenia

AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …

News

Avatar therapy holds potential as adjunct therapy for schizophrenia

November 24, 2017
Medical Communications biotech, drugs, pharma, pharmaceutical, schizophrenia

Experts have developed a new form of therapy for patients living with schizophrenia, by allowing those individuals to speak to …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024